2019 [Available from: Accessed: 13 April 2023]
Originally developed for diabetes control, Semaglutide has gained popularity in the aesthetic and wellness industry due to its impressive efficacy in weight loss
however, the market scenario has shifted focus towards oral GLP-1 receptor agonists, incretin agonists, triple agonists, and amylin-based approaches targeting obesity as a metabolic disease rather than merely focusing on its weight management
In a separate high content screening study we also demonstrated that many pharmaceuticals falling into this basic lipophilic category cause cell loss, DNA fragmentation, and changes to nuclear size, in addition to the lysosomal mass effects [15]
Patients who depend on GLP-1 therapies for diabetes, heart health, or disability face real harm and financial ruin